INCY

Business Context and Reporting Period

Company: Incyte Pharmaceuticals, Inc. (proposed name change to Incyte Genomics, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2000
Business Overview: The Company designs, develops, and markets genomic information-based tools, including database products, software, microarray-based gene expression services, and genomic reagents. It serves pharmaceutical and biotechnology companies as well as academic researchers.

Key Financial Metrics

Material Changes vs. Prior Period

• Capital Raise: In February 2000, the Company completed a significant capital raise, issuing $200 million in convertible subordinated notes (net proceeds ~$196.8 million) and 2 million shares of common stock (net proceeds ~$398.3 million). This increased total cash and marketable securities from $66.9 million at year-end 1999 to $692.2 million at March 31, 2000.
• Revenue Growth: Revenues increased 8.3% to $40.8 million, driven by new products (expression databases, isSNP) and increased custom genomics services.
• Expense Increase: Total costs and expenses rose 41.7% to $56.2 million. Research and Development (R&D) expenses increased 32.3% to $41.3 million due to expanded bioinformatics, SNP discovery, and microarray production. Selling, General, and Administrative (SG&A) expenses increased 76.9% to $14.8 million, driven by sales force expansion and legal fees related to patent litigation.
• Net Loss Expansion: Net loss widened to $8.2 million from $1.9 million, primarily due to higher operating expenses and interest expense ($1.9 million vs. $0.1 million) associated with the new debt, partially offset by a $5.4 million gain on the sale of a long-term investment.
• Joint Venture Accounting Change: Following a financing event by diaDexus, LLC on April 6, 2000, the Company lost significant influence and will switch from the equity method to the cost method of accounting for this investment.

Guidance, Outlook, and Risks

• Outlook: Management expects to report a net loss for the full year 2000 due to continued heavy investment in sequencing, bioinformatics, SNP discovery, and e-commerce programs. Expenditures are expected to increase throughout the year.
• Liquidity: The Company believes existing resources are adequate to satisfy capital needs for at least the next twelve months.
• Legal Risks: The Company is defending two patent infringement lawsuits filed by Affymetrix, Inc. regarding high-density arrays and microarray technology. Affymetrix seeks permanent injunctions and treble damages. The Company cannot estimate potential losses but notes substantial expenses and management diversion are expected to continue.
• Operational Risks: Risks include the unpredictability of database revenues, intense competition in genomics, potential impairment of strategic investments, and the uncertainty of commercializing new technologies like SNP discovery and proteomics.
• Accounting Changes: The Company is evaluating the impact of SAB 101 on revenue recognition, which may result in a charge to operations in the second quarter of 2000 if a policy change is deemed necessary.

Investor Verification Checklist

• Capital Structure: Verify the terms and conversion price ($134.84) of the $200 million convertible notes issued in February 2000.
• Litigation Status: Monitor the status of the Affymetrix patent infringement suits and the PTO interference proceedings, as an adverse outcome could require licensing or result in significant damages.
• Revenue Sustainability: Assess the renewal rates of database collaboration agreements and the commercial viability of new microarray and SNP services.
• Joint Venture Impact: Confirm the financial impact of the accounting method change for diaDexus, LLC effective April 6, 2000.
• Accounting Policy: Watch for the potential cumulative effect charge related to SAB 101 revenue recognition in the Q2 2000 filing.